Synapse - Helena Yu

Results (288)

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC

Meeting Abstract

Yu, H. A.; Oxnard, G. R.; Spira, A. I.; Horn, L.; Weiss, J.; Feng, Y.; West, H. J.; Giaccone, G.; Evans, T. L.; Kelly, R. J.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers

Meeting Abstract

Yu, H. A.; Sima, C. S.; Reales, D.; Jordan, S.; Rudin, C. M.; Kris, M. G.; Michor, F.; Pao, W.; Riely, G. J.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts)

Meeting Abstract

Sequist, L. V.; Goldman, J. W.; Wakelee, H. A.; Camidge, D. R.; Yu, H. A.; Varga, A.; Solomon, B.; Oxnard, G. R.; Ou, S. H. I.; Papadimitrakopoulou, V.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers

Meeting Abstract

Riely, G. J.; Yu, H. A.; Stephens, D.; Pietanza, M. C.; Smith-Marrone, S.; Fiore, J. J.; Goldstein, M.; Sima, C. S.; Kris, M. G.; Ginsberg, M. S.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping

Meeting Abstract

Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer

Meeting Abstract

Oxnard, G. R.; Ramalingam, S. S.; Ahn, M. J.; Kim, S. W.; Yu, H. A.; Saka, H.; Horn, L.; Goto, K.; Ohe, Y.; Cantarini, M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay

Meeting Abstract

Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping

Journal Article

Paik, P. K.; Drilon, A.; Fan, P. D.; Yu, H.; Rekhtman, N.; Ginsberg, M. S.; Borsu, L.; Schultz, N.; Berger, M. F.; Rudin, C. M.; more...
Cancer Discovery (2015)

Fulltext@MSK | Save

Phase I/II study of HSP90 inhibitor AUY922 and Erlotinib for EGFR-Mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors